Linked Life Data

8146565

Source:http://linkedlifedata.com/resource/pubmed/id/8146565

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
20
pubmed:dateCreated
1994-5-5
pubmed:abstractText
Hormone replacement therapy is prescribed to post-menopausal women in order to correct oestrogen deficiency and its short- or long-term consequences. Progestogens are combined with oestrogens to prevent the proliferative effect of the latter on the endometrium. There are three classes of progestogens: normethyl testosterone derivatives, pregnanes and norpregnanes, and natural progesterone. The usual choice is either natural progesterone or 17-hydroxyprogesterone derivatives which do not carry metabolic or vascular risks. The endometrium is protected by simple therapeutic rules: the doses of oestradiol must be minimal to prevent osteoporosis, and this product must not be administered alone for a sequence longer than 13 days. The progestogen sequence must last for 12 days. The wide range of progestogens available in France enables individual adjustments to be made. Using progestogens alone could be interesting in women from whom oestrogenic treatments are contraindicated, in view of their effect on sudden flush and on bone.
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
F
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0035-2640
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
43
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2645-50
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1993
pubmed:articleTitle
[Progestin treatments of menopause].
pubmed:affiliation
Service du Pr P. Poitout, Hôtel-Dieu de Paris.
pubmed:publicationType
Journal Article, English Abstract